Stay updated on Pembrolizumab Amurubicin Combo in Refractory SCLC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Amurubicin Combo in Refractory SCLC Clinical Trial page.

Latest updates to the Pembrolizumab Amurubicin Combo in Refractory SCLC Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedThe study page’s footer revision/version indicator was updated from v3.5.2 to v3.5.3, reflecting a site/version update rather than a change to the trial information itself.SummaryDifference0.1%

- Check19 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.1%

- Check26 days agoNo Change Detected
- Check48 days agoChange DetectedRevision: v3.5.0 was added and Revision: v3.4.3 was removed.SummaryDifference0.1%

- Check62 days agoChange DetectedRevision badge updated from v3.4.2 to v3.4.3.SummaryDifference0.1%

- Check84 days agoChange DetectedMinor site revision update to v3.4.2 from v3.4.1; no changes to study details or page functionality. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check91 days agoChange DetectedThe page now displays Revision: v3.4.1 and no longer displays Revision: v3.4.0.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab Amurubicin Combo in Refractory SCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Amurubicin Combo in Refractory SCLC Clinical Trial page.